Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies

Catalysts

About Prelude Therapeutics

Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines.

What are the underlying business or industry changes driving this perspective?

• The JAK2V617F selective inhibitor directly targets a well established mutation in myeloproliferative neoplasms, and preclinical work suggests it may affect a broad pool of V617F positive PV, MF and ET patients, which could support a larger treated population and higher long term revenue potential.
• The KAT6A selective degrader is aimed at ER positive breast cancer, where existing therapies still face resistance, so any differentiated efficacy and tolerability profile in this large, treatment intensive setting could support sustained prescription demand and future revenue growth.
• The degrader antibody conjugate platform, supported by an expanded AbCellera collaboration, positions Prelude to participate in growing use of targeted biologic delivery, which can create additional out licensing income streams and reduce funding needs through nondilutive capital.
• The exclusive option agreement with Incyte for the JAK2V617F program, with US$60 million already received and the potential for further milestones and royalties, provides external validation of the science and a pathway to material non operating cash inflows that can extend runway and limit dilution pressure on earnings per share.
• Planned IND filings and the expected start of Phase I trials for both the JAK2V617F inhibitor and KAT6A degrader in 2026 give a clear clinical news path, and successful progression through dose escalation could support higher projected future revenue and improve visibility on the timing of potential earnings contributions.

Assumptions

This narrative explores a more optimistic perspective on Prelude Therapeutics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Prelude Therapeutics's revenue will grow by 167.1% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -1064.5% today to 55.6% in 3 years time.
• The bullish analysts expect earnings to reach $111.2 million (and earnings per share of $0.48) by about January 2029, up from $-111.8 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 5.6x on those 2029 earnings, up from -1.9x today. This future PE is lower than the current PE for the US Biotechs industry at 21.5x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.19%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Both the JAK2V617F inhibitor and the KAT6A degrader are still preclinical with first-in-human trials only expected in 2026. Any delay in IND filings, safety findings in IND enabling work or slower than expected dose escalation could push out timelines for potential approvals and reduce the period over which these assets can generate revenue before competing therapies mature, which would weigh on future revenue and earnings.
• Management positions both targets as potentially best in class. However, larger pharma players such as Pfizer and others already have KAT6 and MPN programs several years ahead in the clinic. If competitors secure earlier approvals or show meaningfully better efficacy or safety, Prelude could be pushed into later line use or smaller subpopulations, limiting peak prescription volumes and pressuring long term revenue and net margins.
• The company is relying heavily on preclinical models and degrader chemistry to support expectations for differentiation on efficacy and neutropenia. Human biology can diverge from animal and ex vivo data, so if the JAK2 or KAT6A assets show narrower therapeutic windows, unexpected hematologic toxicity or less robust tumor responses in patients, pricing power and market share could be lower than investors expect, which would impact revenue and constrain earnings improvement.
• The JAK2V617F program is subject to an exclusive, time bound option with Incyte. While the economics are sizable if exercised, Incyte can choose not to proceed after reviewing emerging data. This would remove a potential source of non operating cash inflows and milestone payments, increase Prelude’s funding needs from equity or debt and place more pressure on net margins and earnings per share.
• Prelude’s plan assumes continued access to nondilutive capital from degrader antibody conjugate payload licensing and potential future DAC partnerships. If the DAC field progresses more slowly than expected or partner demand for its payloads is weaker, the company may need to raise additional equity to support R&D through 2027 and beyond, which could increase share count faster than analysts anticipate and dilute any eventual earnings per share growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Prelude Therapeutics is $5.0, which represents up to two standard deviations above the consensus price target of $4.0. This valuation is based on what can be assumed as the expectations of Prelude Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $5.0, and the most bearish reporting a price target of just $3.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $200.0 million, earnings will come to $111.2 million, and it would be trading on a PE ratio of 5.6x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of $2.56, the analyst price target of $5.0 is 48.8% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.